(R*)-DHAP Therapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

(R*)-DHAP Therapy, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Treatment of relapsed Non Hodgkin Lymphoma. Rituximab to be included in CD20 positive patients. 1

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) CD20 + Non-Hodgkin Lymphoma Cisplatin, Cytarabine, Rituximab